亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

医学 前列腺癌 前列腺切除术 泌尿科 内科学 前列腺 肿瘤科 癌症
作者
James Andrew Eastham,Glenn Heller,Susan Halabi,J. Paul Monk,Himisha Beltran,Martin Edwin Gleave,Christopher P. Evans,Steven K. Clinton,Russell Zelig Szmulewitz,Jonathan Coleman,David W. Hillman,Colleen Watt,Saby George,Martin George Sanda,Olwen Mary Hahn,Mary‐Ellen Taplin,John Kellogg Parsons,James Lloyd Mohler,Eric Jay Small,Michael J. Morris
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (26): 3042-3050 被引量:137
标识
DOI:10.1200/jco.20.00315
摘要

PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression–free survival (BPFS) over RP alone. PATIENTS AND METHODS Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m 2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, −0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
缓慢的晓夏完成签到,获得积分10
6秒前
NexusExplorer的应助被zilicai采纳,获得10
9秒前
28秒前
29秒前
36秒前
ding的应助被水长聿采纳,获得10
44秒前
虚心问旋完成签到,获得积分10
45秒前
温婉的乐荷完成签到,获得积分10
45秒前
叶素绿完成签到,获得积分10
52秒前
53秒前
休斯顿完成签到,获得积分10
56秒前
yyyyyz完成签到,获得积分10
58秒前
642463016发布了新的文献求助10
1分钟前
小糊涂仙儿完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
sasa完成签到,获得积分10
1分钟前
酷波er的应助被科研通管家采纳,获得10
1分钟前
1分钟前
大个的应助被叶素绿采纳,获得10
1分钟前
642463016完成签到,获得积分10
1分钟前
倩倩完成签到,获得积分10
1分钟前
欢喜映阳完成签到,获得积分10
1分钟前
Kevin完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
七七完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被zzzjw采纳,获得10
1分钟前
水长聿发布了新的文献求助10
1分钟前
1分钟前
高高笙完成签到,获得积分10
1分钟前
自由的如波完成签到,获得积分10
1分钟前
2分钟前
2分钟前
月亮的喵发布了新的文献求助20
2分钟前
靓丽的淇完成签到,获得积分10
2分钟前
叶素绿发布了新的文献求助10
2分钟前
冷阳发布了新的文献求助10
2分钟前
文曦完成签到 ,获得积分10
2分钟前
hiba发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179810
求助须知:如何正确求助?哪些是违规求助? 9570000
关于积分的说明 21808070
捐赠科研通 7775430
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557220
邀请新用户注册赠送积分活动 2478832